Since most MPM tumours lacking phospho‐CDK4 had high p16 expression, appropriately scored p16 immunohistochemistry (especially regarding intensity and homogeneity of expression [75, 111]), possibly in combination with proliferation markers, could also be used to exclude those intrinsically resistant tumours. The gene discussed is CDKN2A; the disease is neoplasm.